Key result
Desipramine was compared to imipramine in a double-blind controlled trial to investigate relative effectiveness, speed of action, and side-effects, with no results reported in the abstract.
Why the study?
Does desipramine improve effectiveness, speed of action, or side-effects compared to imipramine in patients with depression?
RCT
Double-blind
Does desipramine improve effectiveness, speed of action, or side-effects compared to imipramine in patients with depression?
RCT of desipramine vs imipramine yields no outcome data; leaves open relative effectiveness, onset, and tolerability in depression.
Desipramine (Pertofran) is the monomethyl analogue of imipramine (Tofranil) and is marketed as a potent anti-depressant agent. The literature on this drug has already been adequately reviewed by Rose et al. (1964) and Waldron et al. (1965). It is therefore sufficient to note that earlier reports claiming a more rapid action than imipramine have not been supported by more recent investigations. This paper reports a double-blind controlled comparison of imipramine and desipramine, designed to investigate the relative effectiveness, speed of action and side-effects of these two drugs.
No takes yet. Share an insight, caveat, or question.
ROSE et al. (1967) conducted an RCT in Depression. Desipramine vs. Imipramine was evaluated on Relative effectiveness, speed of action and side-effects. Desipramine was compared to imipramine in a double-blind controlled trial to investigate relative effectiveness, speed of action, and side-effects, with no results reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: